D
Daniel E. Stepan
Researcher at Amgen
Publications - 13
Citations - 1130
Daniel E. Stepan is an academic researcher from Amgen. The author has contributed to research in topics: Motesanib & Thyroid cancer. The author has an hindex of 7, co-authored 13 publications receiving 1087 citations.
Papers
More filters
Journal ArticleDOI
Motesanib diphosphate in progressive differentiated thyroid cancer.
Steven I. Sherman,Lori J. Wirth,Jean Pierre Droz,Michael Hofmann,Lars Bastholt,Renato G. Martins,Lisa Licitra,Michael Eschenberg,Yu Nien Sun,Todd Juan,Daniel E. Stepan,Martin Schlumberger +11 more
TL;DR: Motesanib diphosphate can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive and decrease in serum thyroglobulin concentration during treatment.
Journal ArticleDOI
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer
Martin Schlumberger,Rossella Elisei,Lars Bastholt,Lori J. Wirth,Renato G. Martins,Laura D. Locati,Barbara Jarzab,Furio Pacini,Chantal Daumerie,Jean Pierre Droz,Michael Eschenberg,Yu Nien Sun,Todd Juan,Daniel E. Stepan,Steven I. Sherman +14 more
TL;DR: Although the objective response rate was low, a significant proportion of MTC patients (81%) achieved stable disease while receiving motesanib, and motesanIB trough concentrations were lower compared with differentiated thyroid cancer patients from the same study.
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan,Amit M. Oza,Gary Richardson,Diane Provencher,Vincent L. Hansen,M. Buck,Setsuko K. Chambers,Prafull Ghatage,C. H. Pippitt,John V. Brown,Allan Covens,Raj V. Nagarkar,Margaret Davy,Charles A. Leath,Hoa Nguyen,Daniel E. Stepan,David M. Weinreich,Marjan Tassoudji,Yu Nien Sun,Ignace Vergote +19 more
TL;DR: AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile, and the data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.
Journal ArticleDOI
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
Robert S. Benjamin,Patrick Schöffski,Jörg T. Hartmann,Allan T. van Oosterom,Binh Bui,Justus Duyster,Scott M. Schuetze,Jean-Yves Blay,Peter Reichardt,Lee S. Rosen,Keith M. Skubitz,S. McCoy,Yu Nien Sun,Daniel E. Stepan,Laurence H. Baker +14 more
TL;DR: In this study of patients with imatinib-resistant GIST, motesanib treatment resulted in acceptable tolerability and modest tumor control as evident in the proportion of patients who achieved stable disease and durable stable disease.
Journal ArticleDOI
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Jian-Feng Lu,Erik Rasmussen,Beth Y. Karlan,Ignace Vergote,Lynn Navale,Mita Kuchimanchi,Rebeca Melara,Daniel E. Stepan,David M. Weinreich,Yu-Nien Sun +9 more
TL;DR: Increased exposure to AMG 386 was associated with improved clinical outcomes in recurrent ovarian cancer, supporting the evaluation of a higher dose in future studies.